Glypican 4 may be involved in the adipose tissue redistribution in high-fat feeding C57BL/6J mice with peroxisome proliferators-activated receptor γ agonist rosiglitazone treatment

Experimental and Therapeutic Medicine

Volumn 8, Issue 6, 2014, Pages 1813-1818

  Liu, Li ^a   Gu, Hailun ^a   Zhao, Yue ^a   An, L ^a   Yang, Jun ^a  

^a CHINA MEDICAL UNIVERSITY   (China)

Author keywords

Glypican 4; Obesity; Peroxisome proliferators activated receptor ; Subcutaneous fat; Visceral fat

Indexed keywords

CHOLESTEROL; GLUCOSE; GLYPICAN; GLYPICAN 4; HORMONE; LIPID; ROSIGLITAZONE; TRANSCRIPTION FACTOR SP1; TRANSCRIPTION FACTOR SP3; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ADIPOSE TISSUE; ANIMAL TISSUE; ARTICLE; BIOCHEMISTRY; BODY FAT DISTRIBUTION; BODY WEIGHT; CONTROLLED STUDY; ENERGY BALANCE; GENETIC ANALYSIS; INTRAABDOMINAL FAT; LIPID STORAGE; MALE; MOUSE; MRNA EXPRESSION ASSAY; NONHUMAN; POLYMERASE CHAIN REACTION; PROTEIN EXPRESSION; SUBCUTANEOUS FAT; WESTERN BLOTTING;

EID: 84908217651     PISSN: 17920981     EISSN: 17921015     Source Type: Journal    
DOI: 10.3892/etm.2014.1998     Document Type: Article

References (28)

1. Pischon T, Boeing H, Hoffmann K, et al: General and abdominal adiposity and risk of death in Europe. N Engl J Med 359: 2105-2120, 2008.
2. Tumova S, Woods A and Couchman JR: Heparan sulfate proteoglycans on the cell surface: versatile coordinators of cellular functions. Int J Biochem Cell Biol 32: 269-288, 2000.
3. Fico A, Maina F and Dono R: Fine-tuning of cell signaling by glypicans. Cell Mol Life Sci 68: 923-929, 2011.
4. Li H, Melford K, Judson A and Bensadoun A: Murine glypican-4 gene structure and expression; Sp1 and Sp3 play a major role in glypican-4 expression in 3T3-F442A cells. Biochim Biophys Acta 1679: 141-155, 2004.
5. Gesta S, Blüher M, Yamamoto Y, et al: Evidence for a role of developmental genes in the origin of obesity and body fat distri­bution. Proc Natl Acad Sci USA 103: 6676-6681, 2006.
6. Liu L, Liu HM, Gu HL, et al: Effect of low dose di-2-ethylhexylphthalate exposure on fat distribution of offspring mice in pregnant mice. J Southeast Univ (Med Sci Edi) 33: 147-150, 2014 (In Chinese).
7. Smith SR, De Jonge L, Volaufova J, et al: Effect of pioglitazone on body composition and energy expenditure: a randomized controlled trial. Metabolism 54: 24-32, 2005.
8. Adams M, Montague CT, Prins JB, et al: Activators of peroxisome proliferator-activated receptor gamma have depot-specific effects on human preadipocyte differentiation. J Clin Invest 100: 3149-3153, 1997.
9. Kang JG, Park CY, Ihm SH, et al: Mechanisms of adipose tissue redistribution with rosiglitazone treatment in various adipose depots. Metabolism 59: 46-53, 2010.
10. Laplante M, Festuccia WT, Soucy G, et al: Mechanisms of the depot specificity of peroxisome proliferator-activated receptor gamma action on adipose tissue metabolism. Diabetes 55: 2771-2778, 2006.
11. Laplante M, Sell H, MacNaul KL, et al: PPAR-gamma activation mediates adipose depot-specific effects on gene expression and lipoprotein lipase activity: mechanisms for modulation of postprandial lipemia and differential adipose accretion. Diabetes 52: 291-299, 2003.
12. Ma LJ, Mao SL, Taylor KL, et al: Prevention of obesity and insulin resistance in mice lacking plasminogen activator inhibitor 1. Diabetes 53: 336-346, 2004.
13. Kuda O, Stankova B, Tvrzicka E, et al: Prominent role of liver in elevated plasma palmitoleate levels in response to rosiglitazone in mice fed high-fat diet. J Physiol Pharmacol 60: 135-140, 2009.
14. Liu L, Gu H, Yang J, et al: Adipogenic differentiation is not influenced by lentivirus-mediated shRNA targeting the SOCS3 gene in adipose-derived stromal cells. Mol Biol Rep 37: 2455-2462, 2010.
15. Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(Delta Delta C(T)) Method. Methods 25: 402-408, 2001.
16. Scion image software version 4.0. http://www.bbioo.com/download/58-196-1.html. Accessed March 26, 2008.
17. Hsu WH, Lee BH, Hsu YW and Pan TM: Peroxisome proliferator-activated receptor-γ activators monascin and rosiglitazone attenuate carboxymethyllysine-induced fibrosis in hepatic stellate cells through regulating the oxidative stress pathway but independent of the receptor for advanced glycation end products signaling. J Agric Food Chem 61: 6873-6879, 2013.
18. Chappard D, Marchand-Libouban H, Moreau MF and Baslé MF: Thiazolidinediones cause compaction of nuclear hetero­chromatin in the pluripotent mesenchymal cell line C3H10T1/2 when inducing an adipogenic phenotype. Anal Quant Cytopathol Histopathol 35: 85-94, 2013.
19. Day C: Thiazolidinediones: a new class of antidiabetic drugs. Diabet Med 16: 179-192, 1999.
20. Fonseca V: Effect of thiazolidinediones on body weight in patients with diabetes mellitus. Am J Med 115 Suppl 8A: 42S-48S, 2003.
21. Takasawa K, Kubota N, Terauchi Y and Kadowaki T: Impact of increased PPARgamma activity in adipocytes in vivo on adiposity, insulin sensitivity and the effects of rosiglitazone treatment. Endocr J 55: 767-776, 2008.
22. van Harmelen V, Dicker A, Rydén M, et al: Increased lipolysis and decreased leptin production by human omental as compared with subcutaneous preadipocytes. Diabetes 51: 2029-2036, 2002.
23. Ussar S, Bezy O, Blüher M and Kahn CR: Glypican-4 enhances insulin signaling via interaction with the insulin receptor and serves as a novel adipokine. Diabetes 61: 2289-2298, 2012.
24. Yoo HJ, Hwang SY, Cho GJ, et al: Association of glypican-4 with body fat distribution, insulin resistance, and nonalcoholic fatty liver disease. J Clin Endocrinol Metab 98: 2897-2901, 2013.
25. Sassa Y, Hata Y, Aiello LP, et al: Bifunctional properties of peroxisome proliferator-activated receptor gamma1 in KDR gene regulation mediated via interaction with both Sp1 and Sp3. Diabetes 53: 1222-1229, 2004.
26. Sugawara A, Uruno A, Kudo M, et al: Transcription suppression of thromboxane receptor gene by peroxisome proliferator-activated receptor-gamma via an interaction with Sp1 in vascular smooth muscle cells. J Biol Chem 277: 9676-9683, 2002.
27. Chung SS, Choi HH, Cho YM, Lee HK and Park KS: Sp1 mediates repression of the resistin gene by PPARgamma agonists in 3T3-L1 adipocytes. Biochem Biophys Res Commun 348: 253-258, 2006.
28. Chung SS, Kim JH, Park HS, et al: Activation of PPARgamma negatively regulates O-GlcNAcylation of Sp1. Biochem Biophys Res Commun 372: 713-718, 2008.